On Wednesday, Teva Pharmaceutical ADR hit an important technical milestone, with its Relative Strength (RS) Rating jumping into the 90-plus percentile with an upgrade to 91, up from 71 the day before.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an RS Rating north of 80 as they begin their largest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Teva Pharmaceutical ADR has moved more than 5% past a 19.31 entry in a first-stage cup without handle, meaning it's now out of a proper buy range. Look for the stock to create a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 15%, compared to 9% in the prior report. Revenue increased from 7% to 13%.
Teva Pharmaceutical ADR earns the No. 1 rank among its peers in the Medical-Generic Drugs industry group. Dr. Reddy's Labs ADR and Viatris are also among the group's highest-rated stocks.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
